Home | Welcome to Contract Pharma   
Last Updated Saturday, May 23 2015


Financial Report: AbbVie

Published July 26, 2013
2Q Revenues: $4.7 billion (+4%)

2Q Earnings: $1.1 billion (-16%)

YTD Revenues: $9.0 billion (+4%)

YTD Earnings: $2.0 billion (-5%)

Comments: Humira sales were up 12% to $2.6 billion in the quarter. Kaletra sales were $278 million, up 1%. TriCor/Trilipix sales were down 66% to $107 million due to loss of exclusivity. Niaspan sales were up 10% to $232 million. Synthroid sales were up 24% to $153 million. Zemplar sales were up 13% to $107 million, and Creon sales were up 21% to $106 million.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On